BioSpace News Archive

Business

Mesoblast Finanical Results for the Quarter Ended September 30, 2019

Mesoblast Limited reported operational highlights and financial results for the first quarter ended September 30, 2019.

November 27, 2019
·
10 min read
Biotech Beach

INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar

INmune Bio’s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’s drug development.

November 27, 2019
·
5 min read
Drug Development

ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis

Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks

November 27, 2019
·
13 min read
FDA

FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease

First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy

November 27, 2019
·
12 min read
SkinBioTherapeutics announces deal for development of new cosmetic skincare ingredient based on pioneering skin microbiome research

Agreement with speciality chemical company, Croda International, to design and manufacture a new active skincare ingredient based on SkinBiotix™ technology and investigate specific cosmetic ingredient applications to target.

November 27, 2019
·
4 min read
FDA

SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy

SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy

November 27, 2019
·
7 min read
Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis

Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis

November 27, 2019
·
3 min read
Business

Agios Appoints Jonathan Biller as Chief Legal Officer

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced the appointment of Jonathan Biller to the newly created role of chief legal officer effective December 3, 2019.

November 27, 2019
·
4 min read
Pharm Country

Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference

Verrica Pharmaceuticals Inc. announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2019 at 11:00 a.m. ET.

November 27, 2019
·
3 min read
Policy

Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome

NDA supported by data from two pivotal Phase 3 trials in Dravet syndrome, both of which met the primary and all key secondary endpoints, and an interim analysis from an ongoing open-label extension study

November 27, 2019
·
5 min read